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Summary
Ectopic expression of Oct4, Sox2, cMyc, and Klf4 confers a
pluripotent state upon severaldifferentiated cell types, gener-
ating induced pluripotent stem cells (iPSCs) [1–8]. iPSC deri-
vation is highly inefficient, and the underlying mechanisms
are largely unknown. This low efficiency suggests the exis-
tence of additional cooperative factors whose identification
is critical for understanding reprogramming. In addition, the
therapeutic use of iPSCs relies on the development of effi-
cient nongenetic means of factor delivery, and although
a handful of replacement molecules have been identified,
their use yields a further reduction to the already low
reprogramming efficiency [9–11]. Thus, the identification of
compounds that enhance rather than solely replace the func-
tion of the reprogramming factors will be of great use. Here,
we demonstrate that inhibition of Tgfbb signaling cooperates
in the reprogramming of murine fibroblasts by enabling
faster, more efficient induction of iPSCs, whereas activation
of Tgfbsignaling blocks reprogramming. In addition to exhib-
iting a strong cooperative effect, the Tgfb receptor inhibitor
bypasses the requirement for exogenous cMyc or Sox2,
highlighting its dual role as a cooperative and replacement
factor. The identification of a highly characterized pathway
operating in iPSC induction will open new avenues for
mechanistic dissection of the reprogramming process.
Results and Discussion
We identified Tgfbsignaling as a potential cooperative pathway
in reprogramming during functional validation of a constructed
network that linked retroviral insertion sites across several
mouse iPSC lines [12]. Although the biological validation of
network targets was largely negative, in agreement with statis-
tical analyses suggesting that the network did not differ from
randomly constructed networks, we found that use of a Tgfb
receptor I kinase/activin-like kinase 5 (Alk5) inhibitor could
enhance the efficiency of iPSC derivation.
To induce reprogramming, we infected mouse embryonic
fibroblasts (MEFs) carrying a reverse tetracycline transactiva-
tor (rtTA) transgene with doxycycline (dox)-inducible lentivi-
ruses encoding the four reprogramming factors as previously
described [13]. Administration of the Alk5 inhibitor during the
course of dox induction elicited a striking increase in the
*Correspondence: khochedlinger@helix.mgh.harvard.edunumber of iPSC colonies (Figure 1A). These iPSC clones could
be expanded in the absence of dox, which is a strong indicator
of successful reprogramming [13, 14].
This robust increase in efficiency led us to examine whether
the Alk5 inhibitor could also reduce the temporal requirement
of factor expression and thus reflect an increase in the kinetics
of reprogramming. To test this, we applied dox for three, four,
or five days on four-factor infected MEFs, in either the pres-
ence or the absence of the Alk5 inhibitor (Figure 1B). Although
we were unable to obtain iPSCs with 3 days of dox treatment
in either condition, 4 days of dox treatment was sufficient to
give rise to iPSC colonies at a frequency of 0.0013% in the
inhibitor-treated condition. These colonies were not immedi-
ately apparent and took at least 1 week after dox withdrawal
to emerge. No colonies were observed in the control condition,
demonstrating that the inhibitor promoted faster induction of
iPSCs. Four-day iPSCs expressed the pluripotency markers
Nanog, Oct4, and Sox2 (Figure 1C), and we tested for these
markers three passages after dox withdrawal to ensure a
lack of residual transgene expression [14]. These cells were
also competent to form lineages from all three germ layers in
the context of a teratoma (Figure 1C), providing a functional
test of pluripotency and indicating that use of the Alk5 inhibitor
during reprogramming has no adverse effect on the resulting
iPSCs.
We next sought to establish a dose-response curve for the
Alk5 inhibitor. Using four-factor-infected MEFs, we tested
concentrations of the Alk5 inhibitor over a 1000-fold range,
from 4 nM to 4 mM. Increasing concentrations of inhibitor led
to a progressive increase in the number of iPSC colonies ob-
tained and resulted in a 30-fold enhancement at the highest
dose tested (Figure 1D).
To verify that manipulation of Tgfb signaling affects reprog-
ramming, we investigated whether pathway activation would
inhibit iPSC formation. Using four-factor-infected MEFs, we
applied increasing concentrations of Tgfb1 or Tgfb2 during
the time of dox induction. Under control conditions, we ob-
tained an average of 14 colonies per well (w0.017%); however,
upon addition of 1 ng/ml Tgfb1 or Tgfb2, the efficiency was
reduced to one colony per well (w0.0013%), and at 2.5 ng/ml
and 5 ng/ml, iPSC formation was undetectable (Figure 1E).
The opposing effects of pathway activation and inhibition
confirm the involvement of Tgfb signaling in reprogramming.
To gain further insight into the mode of action of the Alk5
inhibitor, we next examined the temporal window during which
the inhibitor elicited its strongest effect. In four-factor-infected
MEFs, the inhibitor was applied in 4 day intervals from days
0–16 of reprogramming. The largest increase in efficiency
was observed during the first 4 days of reprogramming and
yielded an increase comparable to that obtained by full-time
application of the inhibitor (Figure 1F). A strong enhancement
was also observed with application during the 5–8 day interval,
whereas after dox withdrawal (day 12), the inhibitor appeared
to have no effect.
This early-acting effect prompted us to investigate whether
the Alk5 inhibitor was acting to ‘‘prime’’ the cells and thus to
alter or destabilize the fibroblast state so that it is more
amenable to reprogramming. To test this, we applied the
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Figure 1. The Alk5 Inhibitor Acts Cooperatively to Promote iPSC Induction
(A) Alkaline phosphatase stain for primary iPSC colonies, treated with or without the Alk5 inhibitor (1 mM) during dox induction. MEFs were infected with four
factors, and colonies were stained on day 12 (8 days with dox and 4 days without dox).
(B) Kinetics of reprogramming in MEFs infected with four factors. Dox was applied for 3, 4, or 5 days, with or without the Alk5 inhibitor (2 mM). Colonies were
quantified on day 16 on the basis of morphology; all picked clones were capable of generating dox-independent lines.
(C) Pluripotency of iPSCs derived after 4 days of dox induction with the Alk5 inhibitor. (i–iii) Immunostaining for pluripotency markers, (i) Nanog, (ii) Oct4,
and (iii) Sox2. Colonies were stained after three passages without dox, and staining thus reflects endogenous expression. (iv–vi) Teratoma formation,
demonstrating differentiation into lineages from all three germ layers: (iv) neural tissue, (v) cartilage, and (vi) gut-like epithelium.
(D) Dose-response curve for the Alk5 inhibitor in MEFs induced with four factors. Dox and the inhibitor were applied for 8 days; colonies were quantified on
day 12 on the basis of Oct4 immunostaining.
(E) Effect of Tgfb ligands in reprogramming; four-factor infected MEFs (dox for 12 days; counts on day 16 on the basis of Oct4 immunostaining) were used.
Tgfb concentrations were defined as follows: low, 1 ng/ml; medium, 2.5 ng/ml; and high, 5ng/ml.
(F) Timing of Alk5 inhibitor action. The Alk5 inhibitor (1 mM) was applied in 4 day time intervals. Control = no inhibitor, full-time = inhibitor added on days 1–16.
Dox was withdrawn on day 12, and colonies were quantified on day 16 on the basis of Oct4 immunostaining. Error bars represent standard deviation.
(G) Priming effect of the Alk5 inhibitor. Inhibitor (1 mM) was applied for 3 days before (days 23 to 0) dox induction, during the first 3 days of dox induction
(days 0 to +3), or both (days 23 to +3). Control = no inhibitor. Dox was withdrawn on day 8, and colonies were quantified on day 12 on the basis of Oct4
immunostaining. Error bars represent standard deviation.
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1719inhibitor in 3 day time intervals: before dox administration
(days 23 to 0) to test for a priming effect; during the first
3 days of reprogramming (days 0 to +3) as a control for the effi-
ciency increase; and during both intervals (days 23 to +3) to
test for a synergistic effect. We also included a no-inhibitor
control as a baseline measure (Figure 1G). Administration of
the Alk5 inhibitor prior to expression of the reprogramming
factors (days 23 to 0) led to a slight reduction in efficiency,
thus arguing against a priming effect. In contrast, addition of
the inhibitor during the first 3 days of factor expression led to
an approximately 5-fold enhancement in efficiency, consistent
with our previous findings. The increase in efficiency seen in
the group that received inhibitor during days 23 to +3 was
comparable to that seen in the group that received inhibitor
during days 0 to +3, indicating a lack of a synergistic effect.
It therefore appears that Alk5 inhibition must coincide with
expression of the reprogramming factors in order to elicit its
effect.
One limitation of direct infection is that not every cell
receives the full complement of reprogramming factors, and
there is a large amount of heterogeneity in expression becauseeach cell harbors a unique pattern of viral insertions. It is there-
fore difficult to ascertain whether the increase in efficiency we
have observed so far is due solely to a cooperative effect,
where the inhibitor enhances efficiency in the presence of all
four factors, or to a replacement effect, where the inhibitor
substitutes for specific reprogramming factors. To this end,
we employed a ‘‘secondary system’’ consisting of MEFs iso-
lated from iPSC-derived chimeras. These MEFs contain a
homogenous set of inducible lentiviral integrations that are
permissive for conversion into primary iPSCs; thus, the levels
and stoichiometry of the re-expressed factors are unique to
each MEF line [14, 15].
In two different secondary MEF lines, we tested the effect of
Alk5 inhibition on both the efficiency and kinetics of reprog-
ramming. In this experiment, we applied dox for 4, 6, 8, or
10 days, either in the presence or absence of the Alk5 inhibitor,
then quantified iPSC colony number on day 16. The baseline
levels of reprogramming differed between the two lines
(Figure 2A), which was not unexpected given that efficiency
is dependent upon the levels and stoichiometry of factor
expression, as previously reported [15]. In both lines, addition
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Figure 2. The Alk5 Inhibitor Replaces the Individual Roles of cMyc and Sox2
(A) Kinetics of reprogramming in two secondary MEF lines. Dox was applied for 4, 6, 8, or 10 days with or without the Alk5 inhibitor (2 mM). Colonies were
quantified on day 16 on the basis of morphology and dox independence.
(B) Dose-response curve for the Alk5 inhibitor in secondary STEMCCA MEFs. Dox and the inhibitor were applied for 8 days, and colonies were quantified on
day 12 on the basis of Oct4 immunostaining.
(C) Replacement of the role of cMyc with the Alk5 inhibitor (1 mM). MEFs were infected with either three (OSK) or four (OSMK) factors. Dox was withdrawn on
day 8, and colonies were quantified on day 12 on the basis of morphology and dox independence. Error bars represent standard deviation.
(D) Replacement of Sox2 with the Alk5 inhibitor (1 mM). MEFs were infected with three (OMK) or two (OK) factors and induced with dox for 16 days, then split
on day 18 into media without dox. Image depicts alkaline phosphatase stain of passage 1 cultures.
(E) Pluripotency marker expression in an iPSC line made with the Alk5 inhibitor in the absence of Sox2. Colonies were analyzed after three passages without
dox. (i) Nanog, (ii) Oct4, and (iii) Sox2.
(F) Chimeric mice generated with OMK + inhibitor iPSC lines. iPSCs were labeled with lentivirally delivered tdTomato, injected into diploid blastocysts, and
harvested at E16.5. Three embryos are shown at identical exposures, demonstrating varying degrees of chimerism.
(G) Adult chimera (6 weeks) derived from an OMK + inhibitor iPSC line. Agouti coat color represents iPSC-derived cells.of the Alk5 inhibitor mediated an increase in both efficiency
and kinetics of reprogramming, consistent with a cooperative
effect (Figure 2A). However, the degree to which reprogram-
ming was enhanced was different between the two lines, one
of which showed a 2-fold increase and the other a 30-fold
increase. We reasoned that a purely cooperative action would
produce a consistent increase between the different lines
regardless of variation in factor expression levels, and this
was not the case.
Thus, to further discern between a cooperative and a
replacement effect, we employed a polycistronic construct
linking all four reprogramming factors on a single transcript
(‘‘STEMCCA’’) [16], which in the context of a secondary system
enables expression of all factors in >95% of cells (data not
shown). In such a system, only a cooperative effect would be
revealed because coexpression of all factors precludes factor
replacement. We used these secondary STEMCCA MEFs to
establish another dose-response curve for the Alk5 inhibitor.
In contrast to primary infected MEFs, which demonstrated a
steady increase across the entiredose range tested (Figure 1D),
the STEMCCA MEFs reached a maximum efficiency at 0.5 mM,
representing an approximately 60-fold increase, and efficiency
declined at higher doses (Figure 2B). A similar pattern was
also observed with another inhibitor, SB-431542, that targetsthe type I Tgfb receptors, Alk-4, -5, and -7 (Figure S1). These
data corroborate the notion of a cooperative effect and also
introduce the possibility of a factor-replacement effect that op-
erates at a different dose range, thus explaining the persistent
efficiency increase with higher doses of the Alk5 inhibitor in
primary infected MEFs (Figure 1D) and the decline in the
secondary STEMCCA MEFs.
We therefore set out to investigate whether the Alk5 inhibitor
could function to replace exogenous expression of any of the
reprogramming factors. To this end, we infected primary MEFs
with different combinations of the four factors in the presence
or absence of inhibitor (Table S1) and then scored for iPSC
formation. In the four-factor control infection (OSMK; O =
Oct4, S = Sox2, M = cMyc, and K = Klf4), colonies were already
apparent after 6 days; we therefore withdrew dox on day 8 to
avoid detrimental effects of prolonged factor expression [17].
At this time we also observed colonies in the cMyc replace-
ment condition (OSK + inhibitor), but none in the condition
without the inhibitor; thus, we withdrew dox from these
cultures on day 8 as well. Remarkably, use of the Alk5 inhibitor
(OSK + inhibitor) in place of cMyc resulted in a 2.5-fold higher
efficiency than with the four factors alone (OSK + M), indicating
that Alk5 inhibition was more potent than the action of cMyc in
promoting reprogramming (Figure 2C).
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1721For all of the other replacement conditions, we withdrew dox
on day 16, which we reasoned would provide sufficient time for
reprogramming. Although most conditions did not yield any
obvious colonies, the Sox2 replacement condition contained
numerous colonies morphologically similar to iPSCs. Appear-
ing late in reprogramming, these colonies became readily
visible after 14 days. On the basis of morphology, we counted
50 colonies in the inhibitor-treated culture and four colonies
in the control condition as being identical to iPSCs (data not
shown). Withdrawal of dox, however, led to regression of
many colonies in both conditions, indicating that the cells
were not independent of factor expression. Nonetheless, we
picked colonies from both conditions and tested their potential
to form dox-independent lines. From the control condition, 0/4
were capable of expansion, indicating that infection with the
three factors (OMK) was not sufficient to induce reprogram-
ming, whereas in the inhibitor-treated culture, 3/22 picked
colonies formed dox-independent iPSC lines, demonstrating
successful replacement of Sox2. The efficiency of expansion
was low compared to that of four-factor iPSC clones, where
all picked colonies (6/6 in this set of experiments) were capable
of forming stable dox-independent lines.
Immunostaining of the OMK + inhibitor iPSC lines demon-
strated expression of Nanog, Oct4, and Sox2 (tested after three
passages without dox) (Figure 2E). To further verify expression
of pluripotency genes, we performed quantitative RT-PCR
analysis by using primer sets that distinguish endogenous
and viral transcripts (Figure S2A), which revealed pluripotency
gene activation and viral gene silencing. To functionally assess
pluripotency of the OMK + inhibitor iPSCs, we generated tera-
tomas, which contained lineages from all three germ layers
(Figure S2B). We also tested the ability of these cells to
contribute to chimeric mice; to this end, we labeled iPSCs
with a lentivirus constitutively expressing the red fluorescent
protein, tdTomato, sorted the cells by flow cytometry, and in-
jected them into blastocysts. Mice harvested on embryonic
day E16.5 showed varying degrees of contribution (Figure 2F).
As a more stringent test of pluripotency, we were also able to
generate adult chimeras (Figure 2G), though their potential for
germline transmission has not yet been evaluated. To ensure
that these iPSCs were free of Sox2 viral integrations, we per-
formed Southern blot analysis by using a Sox2 cDNA probe.
No extraneous bands were observed in the OMK + inhibitor
lines, confirming the absence of exogenous Sox2 (Figure S2C).
As a final test to determine whether the Alk5 inhibitor enabled
iPSC formation under any of the replacement conditions, we
passaged the primary cultures in the absence of dox, which
would permit the amplification and selection of rare dox-inde-
pendent cells that may not have been visible in the initial
culture. We excluded OSK and OSMK conditions because
these readily formed iPSCs. Confirming our observations
from the primary cultures, only the Sox2-replacement condi-
tion (OMK + inhibitor) gave rise to dox-independent colonies
(Figure 2D). The control condition (OMK , no inhibitor) also con-
tained colonies that expressed alkaline phosphatase (Fig-
ure 2D, upper left); however, these colonies appeared to be
fibroblastic and did not grow, indicating that they were not
iPSCs. Interestingly, although the Alk5 inhibitor enabled colony
formation in the absence of either cMyc or Sox2, we could not
obtain any colonies in the absence of both factors (OK;
Figure 2D), suggesting that the inhibitor performs distinct func-
tions from Sox2 and cMyc but can preferentially assume their
role in the context of reprogramming with the three remaining
factors.The results presented here demonstrate that Tgfb receptor I
kinase inhibition enhances both the efficiency and kinetics of
reprogramming in a dose-dependent manner, whereas activa-
tion of the Tgfb signaling pathway blocks reprogramming. The
Alk5 inhibitor exerts its strongest effect during the early stages
of iPSC induction and acts in concert with the reprogramming
factors to mediate its effect, rather than converting the fibro-
blasts to a state more amenable to reprogramming. In addition
to its cooperative action, the Alk5 inhibitor can replace the
individual roles of cMyc or Sox2, although it cannot replace
them simultaneously. These results provide the first defined
pathway that both produces a strong cooperative effect and
can preferentially replace the roles of specific reprogramming
factors.
An important remaining question is how Alk5 inhibition acts
on a molecular level to enhance reprogramming. We observed
that application of the inhibitor prior to factor expression was
unable to mediate an increase in efficiency, which is sugges-
tive of a transient effect and/or one that is context dependent,
in that it requires expression of the reprogramming factors to
carry out its role. The observation that the Alk5 inhibitor acts
early in reprogramming raises the question of whether it helps
shut down the fibroblast gene-expression program. In support
of this, it has been shown that activation of Tgfb signaling can
promote an epithelial-to-mesenchymal transition [18]; fibro-
blast reprogramming involves a mesenchymal-to-epithelial
conversion, which may be enhanced by inhibition of the Tgfb
signaling pathway.
An enhancement in efficiency could also be mediated
through increased proliferation. We tested this possibility by
examining proliferation rates during reprogramming but found
that the inhibitor led to a decrease in proliferation around day
6 (Figure S3A). We noted that the inhibitor also mitigated the
decrease in cell number that normallyaccompanies reprogram-
ming (day 2) (Figure S3A); however, the magnitude of this effect
was unlikely to explain the large increase in overall reprogram-
ming efficiency. Furthermore, quantification of apoptosis with
Annexin V staining showed a negligible difference between
inhibitor-treated and untreated cells (Figure S3B).
As yet another possibility, we tested the Alk5 inhibitor in
the context of reprogramming by cell fusion (embryonic stem
cells + MEFs), which led to a negative result (data not shown).
This observation raises the question of whether Alk5 inhibition
acts on direct-reprogramming pathways that are already
operational in embryonic stem cells (ESCs) or whether the
mechanisms of reprogramming by direct factors and cell
fusion are fundamentally different.
The finding that the Alk5 inhibitor could replace either
cMyc or Sox2, but not both, suggests that its functions are
distinct from those of these reprogramming factors. It is
possible that replacement of both factors could occur with
different doses of the inhibitor or with a longer period of
dox administration; however, the conditions we used that
enabled replacement of the individual factors were unable
to elicit simultaneous replacement, indicating a unique
mode of action. We tested whether the Alk5 inhibitor simply
led to induction of Sox2 or cMyc expression; however, anal-
ysis by qRT-PCR revealed that only cMyc was significantly
induced (1.3-fold) in OSK + inhibitor-treated cells (Figure S4),
and there was no significant induction of Sox2 or cMyc in any
of the other cells (OMK or OSMK). A possibility is that the
Alk5 inhibitor acts on a pathway that completely bypasses
the need for the individual reprogramming factors; for
instance, it has been shown that Sox2 is not required for
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cytes [19].
Several Tgfb superfamily members represent important
contributors to the pluripotent state. For instance, BMP4
signaling helps maintain mouse ESCs in an undifferentiated
state [20], and use of an Alk5 inhibitor in conjunction with
GSK3b and MEK inhibitors facilitates rat and human iPSC-
line propagation and supports a mouse ESC-like phenotype
[21]. In contrast to its pluripotency-promoting effect in mouse
ESCs, BMP4 induces differentiation of human ESCs toward
trophectoderm [22], whereas Activin signaling maintains pluri-
potency of hESCs [23]. The differential requirements of Tgfb
signaling in mouse and human ESCs may explain why we did
not observe an increase in the efficiency of human fibroblast
reprogramming (data not shown); it will be interesting to see
whether activation of other pathways that promote the undif-
ferentiated state also enhance reprogramming.
The highly characterized nature of the Tgfb signaling
pathway makes it an attractive model for examining how inter-
actions between downstream targets and the four factors
synergize to enhance reprogramming. The identification of
such pathways will greatly facilitate our understanding of
reprogramming at the molecular level and potentially lead to
the discovery of novel targets that promote reprogramming
and are of therapeutic value.
Experimental Procedures
Virus Production
Vectors were constructed as previously described [13]. Viruses were
produced and titered by the University of Iowa Gene Transfer Vector
Core. For all experiments, cells were infected overnight at a multiplicity of
infection of 10 in the presence of 6 mg/ml polybrene, which was experimen-
tally determined to infect >90% of cells.
Cell Culture and iPSC Induction
Cells were obtained from mice harboring a reverse tetracycline transactiva-
tor (rtTA) in the Rosa locus [24]. Fibroblasts were derived from E14.5 mice;
all experiments were conducted prior to passage 3. To induce reprogram-
ming, we infected cells with the viral cocktail, then split them two days
later into ESC media (15% FBS, Invitrogen; 1000 U/ml LIF) with doxycycline
(1mg/ml). Fibroblast feeder cells were used only to maintain iPSC lines and
not during reprogramming. The Alk5 inhibitor (Calbiochem/EMD 616452)
was used at a concentration of 1 mM unless otherwise noted. The Alk-4/5/
7 inhibitor, SB-431542, was obtained from Sigma; Tgfb ligands were
obtained from Peprotech (Tgfb1, 100-21; Tgfb2, 100-35).
Alkaline Phosphatase and Immunostaining
Alkaline phosphatase (AP) staining was done with an AP substrate kit
according to manufacturer directions (VectorLabs, SK-5100). The following
antibodies were used for immunostaining: a-Nanog (1:200, ab21603,
Abcam), a-Oct4 (1:100sc-8628, Santa Cruz Biotech), and a-Sox2 (1:200,
AB5603, Millipore).
Quantitative RT-PCR
RNA was extracted with a Qiagen RNeasy kit (74104), then converted to
cDNA with the Superscript III First-Strand synthesis system (Invitrogen)
and oligo-dT primers. qRT-PCRs were carried out with Brilliant II SYBR
Green mix (Stratagene) and run on a Stratagene MXPro400. Reactions
were carried out in duplicate with 2RT controls, and data were analyzed
by the delta-delta Ct method.
Apoptosis Assay
Annexin V and propidium iodide staining were done with the Annexin V-FITC
kit (BD Pharmingen, 556547) according to manufacturer directions. Cells
were analyzed by flow cytometry on a FACSCalibur (BD).Teratomas
A 25 cm2 equivalent of confluent iPSCs grown on feeders was harvested
and injected subcutaneously into SCID mice. Teratomas were harvested
3 weeks later and stained with hematoxylin and eosin.
Blastocyst Injections
BDF1 females were superovulated with pregnant mare serum gonadotropin
and hCG, then mated with BDF1 males. Blastocysts were flushed from
uterine horns on day 3.5, and 10–20 labeled iPSCs were injected per blasto-
cyst. Swiss-webster mice were set up with vasectomized males and used as
recipients for the injected blastocysts.
Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://www.cell.com/current-biology/
S0960-9822(09)01598-X.
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